Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

Phase 2

Recruiting

Conditions: Lymphatic Malformations

Interventions: Drug: Alpelisib
Drug: Placebo

First Posted Date: 2023-07-17

Last Posted Date: 2024-11-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 230

Registration Number: NCT05948943

Locations: 🇺🇸
Lucile Packard Childrens Hosp, Palo Alto, California, United States
🇺🇸
WA Uni School Of Med, Saint Louis, Missouri, United States
🇺🇸
Cinn Children Hosp Medical Center, Cincinnati, Ohio, United States

and more 4 locations

Asciminib RMP Study

Recruiting

Conditions: Chronic Myeloid Leukemia

Interventions: Other: Asciminib

First Posted Date: 2023-07-13

Last Posted Date: 2024-03-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT05943522

Locations: 🇰🇷
Novartis Investigative Site, Taegu, Korea, Republic of

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Phase 3

Recruiting

Conditions: Oligometastatic Prostate Cancer (OMPC)

Interventions: Drug: AAA617

First Posted Date: 2023-07-11

Last Posted Date: 2024-11-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 450

Registration Number: NCT05939414

Locations: 🇺🇸
Virginia Oncology Associates, Norfolk, Virginia, United States
🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸
Rocky Mountain Cancer Centers, Longmont, Colorado, United States

and more 10 locations

Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Phase 3

Recruiting

Conditions: Atypical Hemolytic Uremic Syndrome

Interventions: Drug: Iptacopan

First Posted Date: 2023-07-07

Last Posted Date: 2024-11-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 50

Registration Number: NCT05935215

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.

Recruiting

Conditions: Hidradenitis Suppurativa

Interventions: Other: secukinumab

First Posted Date: 2023-06-28

Last Posted Date: 2024-07-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 600

Registration Number: NCT05921994

Locations: 🇩🇪
Novartis Investigative Site, Wuppertal, Germany

Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings

Completed

Conditions: Diffuse Large B-cell Lymphoma

First Posted Date: 2023-06-26

Last Posted Date: 2023-06-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1031

Registration Number: NCT05918809

Locations: 🇺🇸
Novartis, East Hanover, New Jersey, United States

An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Phase 3

Recruiting

Conditions: Hyperlipoproteinemia (a)

Interventions: Drug: Pelacarsen

First Posted Date: 2023-06-12

Last Posted Date: 2024-09-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT05900141

Locations: 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany

Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia

Completed

Conditions: Chronic Myeloid Leukaemia

First Posted Date: 2023-06-08

Last Posted Date: 2023-06-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 555

Registration Number: NCT05893836

Locations: 🇬🇧
Haematological Malignancy Research Network, York, United Kingdom

Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.

Phase 3

Completed

Conditions: Primary Hypercholesterolemia or Mixed Dyslipidemia

Interventions: Drug: Matching Placebo for Inclisiran
Drug: Inclisiran

First Posted Date: 2023-06-05

Last Posted Date: 2024-12-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 207

Registration Number: NCT05888103

Locations: 🇨🇳
Novartis Investigative Site, Tianjin, China

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

Phase 3

Recruiting

Conditions: Follicular Lymphoma (FL)

Interventions: Biological: Tisagenlecleucel
Drug: Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.
Drug: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles
Drug: Lymphodepleting chemotherapy
Other: Corticosteroids and/or Radiation (Bridging therapy)

First Posted Date: 2023-06-05

Last Posted Date: 2024-12-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 108

Registration Number: NCT05888493

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy